BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kasai K, Ushio A, Kasai Y, Sawara K, Miyamoto Y, Oikawa K, Kuroda H, Takikawa Y, Suzuki K. Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion. Cancer. 2012;118:3302-3310. [PMID: 22072099 DOI: 10.1002/cncr.26648] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Vera MC, Lorenzetti F, Lucci A, Comanzo CG, Ceballos MP, Pisani GB, Alvarez MDL, Quiroga AD, Carrillo MC. Vitamin K2 supplementation blocks the beneficial effects of IFN-α-2b administered on the early stages of liver cancer development in rats. Nutrition 2019;59:170-9. [DOI: 10.1016/j.nut.2018.08.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
2 Vacchelli E, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunostimulatory cytokines. Oncoimmunology 2013;2:e24850. [PMID: 24073369 DOI: 10.4161/onci.24850] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 4.9] [Reference Citation Analysis]
3 Yashima Y, Sato S, Kawai T, Sugimoto T, Sato T, Kanda M, Obi S. Intraarterial 5-fluorouracil and interferon therapy is safe and effective for nonresectable biliary tract adenocarcinoma. Hepatol Int 2015;9:142-8. [PMID: 25788388 DOI: 10.1007/s12072-014-9583-z] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
4 Hong YP, Li ZD, Prasoon P, Zhang Q. Immunotherapy for hepatocellular carcinoma: From basic research to clinical use. World J Hepatol 2015; 7(7): 980-992 [PMID: 25954480 DOI: 10.4254/wjh.v7.i7.980] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
5 Zhang K. Overview of Interferon: Characteristics, signaling and anti-cancer effect. Arch Biotechnol Biomed 2017;1:001-16. [DOI: 10.29328/journal.hjb.1001001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
6 Longo V, Gnoni A, Casadei Gardini A, Pisconti S, Licchetta A, Scartozzi M, Memeo R, Palmieri VO, Aprile G, Santini D, Nardulli P, Silvestris N, Brunetti O. Immunotherapeutic approaches for hepatocellular carcinoma. Oncotarget 2017;8:33897-910. [PMID: 28420805 DOI: 10.18632/oncotarget.15406] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 9.8] [Reference Citation Analysis]
7 Kasai K, Kooka Y, Suzuki Y, Suzuki A, Oikawa T, Ushio A, Kasai Y, Sawara K, Miyamoto Y, Oikawa K, Takikawa Y. Efficacy of hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic pegylated interferon α-2b for advanced intrahepatic cholangiocarcinoma. Ann Surg Oncol 2014;21:3638-45. [PMID: 24817369 DOI: 10.1245/s10434-014-3766-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
8 Okada Y, Wang T, Kasai K, Suzuki K, Takikawa Y. Regulation of transforming growth factor is involved in the efficacy of combined 5-fluorouracil and interferon alpha-2b therapy of advanced hepatocellular carcinoma. Cell Death Discov 2018;4:42. [PMID: 29560281 DOI: 10.1038/s41420-018-0040-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Cao Z, Chen X, Lan L, Zhang Z, Du J, Liao L. Active hexose correlated compound potentiates the antitumor effects of low-dose 5-fluorouracil through modulation of immune function in hepatoma 22 tumor-bearing mice. Nutr Res Pract 2015;9:129-36. [PMID: 25861418 DOI: 10.4162/nrp.2015.9.2.129] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
10 Vera MC, Lucci A, Ferretti AC, Abbondanzieri AA, Comanzo CG, Lorenzetti F, Pisani GB, Ceballos MP, Alvarez ML, Carrillo MC, Quiroga AD. The chemoprotective effects of IFN-α-2b on rat hepatocarcinogenesis are blocked by vitamin E supplementation. J Nutr Biochem 2021;96:108806. [PMID: 34147603 DOI: 10.1016/j.jnutbio.2021.108806] [Reference Citation Analysis]
11 Shakado S, Sakisaka S, Chayama K, Okanoue T, Toyoda J, Izumi N, Matsumoto A, Takehara T, Ido A, Hiasa Y, Yoshioka K, Nomura H, Ueno Y, Seike M, Kumada H. Alpha-fetoprotein and des-gamma-carboxy-prothrombin at twenty-four weeks after interferon-based therapy predict hepatocellular carcinoma development. World J Hepatol 2015; 7(27): 2757-2764 [PMID: 26644819 DOI: 10.4254/wjh.v7.i27.2757] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
12 Ceballos MP, Parody JP, Quiroga AD, Casella ML, Francés DE, Larocca MC, Carnovale CE, Alvarez Mde L, Carrillo MC. FoxO3a nuclear localization and its association with β-catenin and Smads in IFN-α-treated hepatocellular carcinoma cell lines. J Interferon Cytokine Res 2014;34:858-69. [PMID: 24950290 DOI: 10.1089/jir.2013.0124] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
13 Nemoto T, Matsuda H, Nosaka T, Saito Y, Ozaki Y, Hayama R, Naito T, Takahashi K, Ofuji K, Ohtani M, Hiramatsu K, Suto H, Nakamoto Y. Comparison of hepatic arterial infusion chemotherapy and sorafenib in elderly patients with advanced hepatocellular carcinoma: A case series. Mol Clin Oncol 2014;2:1028-34. [PMID: 25279193 DOI: 10.3892/mco.2014.371] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Wu J, Huang WJ, Wang HY, Wang YF, Peng BG, Zhou Q. Arterial infusion of 5-fluorouracil combined with subcutaneous injection of pegylated interferon alpha-2b in treating unresectable hepatocellular carcinoma with portal vein tumor thrombus. Med Oncol 2015;32:65. [PMID: 25691293 DOI: 10.1007/s12032-015-0491-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Wang M, Liu H, Zhang X, Zhao W, Lin X, Zhang F, Li D, Xu C, Xie F, Wu Z, Yang Q, Li X. Lack of MOF Decreases Susceptibility to Hypoxia and Promotes Multidrug Resistance in Hepatocellular Carcinoma via HIF-1α. Front Cell Dev Biol 2021;9:718707. [PMID: 34540836 DOI: 10.3389/fcell.2021.718707] [Reference Citation Analysis]
16 Yasui D, Murata S, Ueda T, Sugihara F, Onozawa S, Kawamoto C, Kumita S. Novel treatment strategy for advanced hepatocellular carcinoma: combination of conventional transcatheter arterial chemoembolization and modified method with portal vein occlusion for cases with arterioportal shunt: a preliminary study. Acta Radiol. 2018;59:266-274. [PMID: 28651444 DOI: 10.1177/0284185117717762] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]